Harvard Bioscience (HBIO) Receivables - Net (2010 - 2026)

Harvard Bioscience (HBIO) has reported Receivables - Net for 17 consecutive years, with $14.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables - Net rose 21.47% year-over-year to $14.5 million in Q2 2026; TTM through Jun 2026 was $14.5 million, a 21.47% increase from a year earlier, with the FY2025 full-year figure at $16.0 million, up 7.92% from the prior year.
• Receivables - Net was $14.5 million for Q2 2026 at Harvard Bioscience, roughly flat from $14.6 million in the prior quarter.
• Over five years, Receivables - Net peaked at $20.3 million in Q1 2022 and troughed at $11.9 million in Q2 2025.
• A 5-year average of $15.2 million and a median of $15.0 million in 2022 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net decreased 26.13% in 2024 and rose 21.47% in 2026, its largest moves.
• Over 5 years, Receivables - Net stood at $16.7 million in 2022, then retreated by 3.63% to $16.1 million in 2023, then decreased by 7.66% to $14.9 million in 2024, then grew by 7.92% to $16.0 million in 2025, then dropped by 9.62% to $14.5 million in 2026.
• The last three Receivables - Net figures came in at $14.5 million (Q2 2026), $14.6 million (Q1 2026), and $16.0 million (Q4 2025), per Business Quant data.